New Survey from Philip Morris International Reveals Strong Societal Support for Disruptive Innovations to Drive Public Health Progress
27 September 2022 - 8:00AM
Business Wire
Nearly 7 in 10 respondents believe governments
and businesses must work together to achieve significant change
faster
A new international survey released today by Philip Morris
International Inc. (PMI) (NYSE: PM) reveals that despite broad
public support for disruptive innovation to address global
challenges, issues such as lack of equal access are likely to stall
progress. Commissioned by PMI and conducted by independent research
agency Povaddo, the survey shows that 89 percent of adults across
14 countries believe that new technologies and innovations can play
an important role in improving public health. However, 38 percent
feel such innovations are not accessible to all citizens in their
countries.
The more than 17,000 survey respondents aged 21 and older
believe that the development and adoption of new technologies,
innovations, and capabilities can enable significant progress
against a range of issues over the next 10 to 20 years,
including:
- Encouraging healthier eating habits (78 percent)
- Ensuring quality and affordable healthcare for all (72
percent)
- Reducing smoking rates (65 percent)
- Eliminating hunger and malnourishment (62 percent)
“Disruptive innovation can drive progress for the world and
achieve things few people imagined possible until recently,” said
Grégoire Verdeaux, Senior Vice President, External Affairs, PMI.
“But when the benefits of that disruption are not equally available
to all, innovation fails to achieve its full potential. Pragmatic
policy frameworks that anticipate innovations are needed so
businesses and governments can ensure more equitable outcomes and a
lasting impact for all.”
The international survey also highlights the potential of
positive disruption in tobacco harm reduction—with 64
percent of respondents stating that new technologies and
innovations can play an important role in helping replace
cigarettes with less harmful alternatives for those adults who
would otherwise continue to smoke. These better alternatives exist
today thanks to advances in science and technology and significant
investments by PMI and other companies.
However, progress is being hindered by public policies that have
failed to keep up with innovation. In many countries, the only
tobacco or nicotine-containing products that can legally be sold
are cigarettes. And in markets where better alternatives are
available, adult smokers often cannot access these products or
receive accurate information about them.
“Today, with technological advances and scientific validation,
we have an unprecedented opportunity to enact a major public health
breakthrough—to effectively eradicate smoking faster,” added
Verdeaux. “We can make this the tipping point at which millions of
adult smokers are given accurate information about and access to
innovative smoke-free products that are a much better choice than
continued smoking. But for that to happen, all parties—businesses,
governments, public health authorities—must work together.”
To deliver positive change quickly and equitably, fresh thinking
and concerted action are needed. Findings from the international
survey highlight the public’s frustration with policymakers’
performance to date. Specifically:
- 41 percent of respondents believe that government and public
health authorities in their countries have done a poor job of
embracing new technologies and innovations to improve public
health.
- 47 percent believe government and public health authorities
have done a poor job of ensuring everyone in their country has
access to the latest innovations and technologies that can improve
public health.
Survey respondents point to collaboration between government and
the private sector as a catalyst of innovation, placing it just
below capital investments by private companies. Asked to select the
greatest enablers of innovation, respondents returned these
results:
- Entrepreneurship (76 percent of respondents say it enables
innovation)
- Consumer demand (74 percent)
- Capital investments by private-sector companies (72
percent)
- Collaboration between government and the private sector (69
percent)
- Competition within the private sector (69 percent)
Select results of this new international survey are featured in
PMI’s latest white paper, Rethinking
Disruption: Innovating for Better in an Era of Division,
which explores the dynamics of positive disruption and its
potential to drive meaningful progress on tobacco harm reduction
and other critical issues. To bring about much-needed change and
accelerate the end of smoking, PMI is transforming for good, having
fundamentally revamped not just its product portfolio but also its
purpose, business model, value chain, and practices. To learn more
about how PMI is delivering a smoke-free future faster, visit
pmi.com/rethinkdisruption.
Survey methodology
Povaddo conducted the online survey on behalf of PMI between
July 19 and August 10, 2022. The survey was fielded among 17,207
general population adults aged 21 and older and a booster sample of
201 policy elites and 281 business elites in 14 countries:
Argentina, Brazil, Colombia, Costa Rica, Dominican Republic,
Germany, Italy, Japan, Mexico, Panama, Philippines, Sweden, United
Kingdom, and United States. Approximately 1,100 interviews were
collected in each country. Data have been weighted by age, gender,
and nicotine product use per market to match national statistics.
Results are accurate to a margin of error of ±1 percent. A similar
study was commissioned in Saudi Arabia.
Philip Morris International: Delivering a Smoke-Free Future
Philip Morris International (PMI) is a leading international
tobacco company working to deliver a smoke-free future and evolving
its portfolio for the long term to include products outside of the
tobacco and nicotine sector. The company’s current product
portfolio primarily consists of cigarettes and smoke-free products,
including heat-not-burn, vapor, and oral nicotine products, which
are sold in markets outside the U.S. Since 2008, PMI has invested
more than USD 9 billion to develop, scientifically substantiate,
and commercialize innovative smoke-free products for adults who
would otherwise continue to smoke, with the goal of completely
ending the sale of cigarettes. This includes the building of
world-class scientific assessment capabilities, notably in the
areas of pre-clinical systems toxicology, clinical and behavioral
research, as well as post-market studies. The U.S. Food and Drug
Administration (FDA) has authorized the marketing of versions of
PMI’s IQOS Platform 1 devices and consumables as Modified Risk
Tobacco Products (MRTPs), finding that exposure modification orders
for these products are appropriate to promote the public health. As
of June 30, 2022, excluding Russia and Ukraine, PMI’s smoke-free
products were available for sale in 70 markets, and PMI estimates
that approximately 13.2 million adults around the world had already
switched to IQOS and stopped smoking. With a strong foundation and
significant expertise in life sciences, in February 2021 PMI
announced its ambition to expand into wellness and healthcare areas
and deliver innovative products and solutions that aim to address
unmet consumer and patient needs. For more information, please
visit www.pmi.com and www.pmiscience.com.
# # #
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220926005339/en/
David Fraser Philip Morris International David.Fraser@pmi.com
+41 (0)58 242 4500
Philip Morris (NYSE:PM)
Historical Stock Chart
Von Mär 2024 bis Apr 2024
Philip Morris (NYSE:PM)
Historical Stock Chart
Von Apr 2023 bis Apr 2024